A New Approach to Solving Mental Health Challenges

Enveric is dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders

Our approach

Enveric researchers have been focused on synthesizing novel small molecule therapeutics that leverage a combination approach of synthetic chemistry and synthetic biology.

Enveric has adopted an agnostic approach to synthesis resulting in the creation of a proprietary library, the Psybrary™, which contains a large and diverse portfolio of drug candidates encompassing significant structural diversity and exhibiting therapeutically relevant neuroactive properties. The Psybrary™ includes 15 patent families.

To date, several hundred new chemical entities have been synthesized.

EVM201 Series —Enhanced Drug-Like Properties

Enveric’s Psybrary™ has given rise to the EVM201 Series, next generation synthetic psilocybin analogues that are considered prodrugs of the active metabolite—psilocin. Enveric’s has completed screening and characterization of its portfolio of psilocin prodrugs, comprised of nine distinct classes. All molecules were rationally designed to achieve altered metabolic and pharmacokinetic properties with the intention of improving the drug-like properties and pharmacological profile of EVM201 drug candidates compared to the natural compound, psilocybin.

These next-generation compounds aim to improve the patient’s therapeutic response, while minimizing side effects.

Desired attributes

  • Optimized delivery route (oral, intra-nasal, buccal or intravenous)
  • Wide range of dosing flexibility
  • Faster access to target (brain)
  • Reduction in dose required to achieve therapeutic benefit:
    • Higher brain penetration
    • Quick onset of action
    • Lower side effects (GI, systemic, etc.)

EVM201 Molecules Release Psilocin and Have Unique Profiles in Animal Models

Data on File; Enveric Biosciences.
Data on File; Enveric Biosciences.
PSIL: Psilocybin | Data on File; Enveric Biosciences.
PSIL: Psilocybin | Data on File; Enveric Biosciences.

EVM301 Series — New Chemical Entities

Enveric’s third generation of therapeutics are intended to offer a holistic approach for treating central nervous system disorders. The EVM301 Series is progressing through early discovery and characterization efforts, utilizing proven strategies and tools to accelerate the activities for defining additional promising neuroactive drug candidates.

Mechanism of Action
Treatment Paradigm
New Chemical Entities

Discovering Next-generation Treatments for Mental Illness

Our mission is to pioneer a paradigm shift and generate new solutions with the potential to have profound effects on patients and their families, and to deliver life-changing medicines for diseases affecting the brain, such as anxiety, depression, and addiction.